Huang David, Xia Ping, Akazawa Pam, Akazawa Clayton, Quivey Jeanne M, Verhey Lynn J, Kaplan Michael, Lee Nancy
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):158-68. doi: 10.1016/s0360-3016(03)00080-4.
PURPOSE: To compare intensity-modulated radiotherapy (IMRT) treatment planning with three-dimensional conformal radiotherapy (3D-CRT) planning for paranasal sinus carcinoma. MATERIALS AND METHODS: Treatment plans using traditional 3-field technique, 3D-CRT planning, and inverse planning IMRT were developed for a case of paranasal sinus cancer requiring adjuvant radiotherapy. Plans were compared with respect to dose conformality, dose-volume histograms, doses to critical normal tissues, and ease of treatment delivery. RESULTS: The inverse-planned IMRT technique was more conformal around the tumor target volume than conventional techniques. The dose-volume histograms demonstrated significantly better critical normal-tissue sparing with the IMRT plans, while able to deliver a minimum dose of 60 Gy to the clinical tumor volume and 70 Gy to the gross tumor volume. Acute toxicities in our analysis were minimal. CONCLUSIONS: IMRT planning provided improved tumor target coverage when compared to 3D-CRT treatment planning. There was significant sparing of optic structures and other normal tissues, including the brainstem. Inverse planning IMRT provided the best treatment for all paranasal sinus carcinomas, but required stringent immobilization criteria. Further studies are needed to establish the true clinical advantage of this modality.
目的:比较调强放射治疗(IMRT)与三维适形放射治疗(3D-CRT)用于鼻窦癌的治疗计划。 材料与方法:针对1例需要辅助放疗的鼻窦癌患者,制定了使用传统3野技术、3D-CRT计划和逆向计划IMRT的治疗计划。从剂量适形性、剂量体积直方图、关键正常组织的剂量以及治疗实施的难易程度等方面对计划进行了比较。 结果:与传统技术相比,逆向计划IMRT技术在肿瘤靶区周围的适形性更好。剂量体积直方图显示,IMRT计划对关键正常组织的保护明显更好;同时能够向临床肿瘤体积给予至少60 Gy的剂量,向大体肿瘤体积给予70 Gy 的剂量。我们分析中的急性毒性极小。 结论:与3D-CRT治疗计划相比,IMRT计划能更好地覆盖肿瘤靶区。对视神经结构及包括脑干在内的其他正常组织有显著的保护作用。逆向计划IMRT为所有鼻窦癌提供了最佳治疗,但需要严格的固定标准。需要进一步研究以确定这种治疗方式的真正临床优势。
Int J Radiat Oncol Biol Phys. 2003-5-1
Int J Radiat Oncol Biol Phys. 2003-5-1
Int J Radiat Oncol Biol Phys. 2003-5-1
Int J Radiat Oncol Biol Phys. 2005-8-1
Int J Radiat Oncol Biol Phys. 2003-3-1
Int J Radiat Oncol Biol Phys. 2004-7-1
Int J Radiat Oncol Biol Phys. 2000-10-1
Int J Radiat Oncol Biol Phys. 2005-10-1
Eur Arch Otorhinolaryngol. 2025-3-28
Cancers (Basel). 2021-9-25
J Neurooncol. 2020-12
Curr Treat Options Oncol. 2020-1-16
Strahlenther Onkol. 2015-1